Du Kun, Zeng Qinlong, Jiang Mingjun, Hu Zhiqing, Zhou Miaojin, Xia Kun
MOE Key Laboratory of Rare Pediatric Diseases, College of Basic Medical Sciences, Hengyang Medical School, University of South China, Hengyang 421009, China.
Department of Psychiatry, The Seventh Affiliated Hospital, Hengyang Medical School, University of South China (Hunan Provincial Veterans Administration Hospital), Changsha 410006, China.
Biosensors (Basel). 2025 Jun 4;15(6):360. doi: 10.3390/bios15060360.
Nucleic acid detection technology is crucial for molecular diagnosis. The advent of CRISPR/Cas12a-based nucleic acid detection has considerably broadened its scope, from the identification of infectious disease-causing microorganisms to the detection of disease-associated biomarkers. This innovative system capitalizes on the non-specific single-strand cleavage activity of Cas12a upon target DNA recognition. By employing a fluorescent probe in the form of a single-stranded DNA/RNA, this technology enables the observation of fluorescence changes resulting from nonspecific cleavage, thereby facilitating detection. CRISPR/Cas12a-based detection systems can be regarded as a new type of biosensor, offering a practical and efficient approach for nucleic acid analysis in various diagnostic settings. CRISPR/Cas12a-based biosensors outperform conventional nucleic acid detection methods in terms of portability, simplicity, speed, and efficiency. In this review, we elucidate the detection principle of CRISPR/Cas12a-based biosensors and their application in disease diagnostics and discuss recent innovations and technological challenges, aiming to provide insights for the research and further development of CRISPR/Cas12a-based biosensors in personalized medicine. Our findings show that although CRISPR/Cas12a-based biosensors have considerable potential for various applications and theoretical research, certain challenges remain. These include simplifying the reaction process, enhancing precision, broadening the scope of disease detection, and facilitating the translation of research findings into clinical practice. We anticipate that ongoing advancements in CRISPR/Cas12a-based biosensors will address these challenges.
核酸检测技术对分子诊断至关重要。基于CRISPR/Cas12a的核酸检测的出现极大地拓宽了其应用范围,从识别引起传染病的微生物到检测疾病相关生物标志物。这一创新系统利用了Cas12a在识别靶DNA时的非特异性单链切割活性。通过采用单链DNA/RNA形式的荧光探针,该技术能够观察到非特异性切割引起的荧光变化,从而便于检测。基于CRISPR/Cas12a的检测系统可被视为一种新型生物传感器,并为各种诊断环境中的核酸分析提供了一种实用且高效的方法。基于CRISPR/Cas12a的生物传感器在便携性、简易性、速度和效率方面优于传统核酸检测方法。在本综述中,我们阐明了基于CRISPR/Cas12a的生物传感器的检测原理及其在疾病诊断中的应用,并讨论了近期的创新和技术挑战,旨在为基于CRISPR/Cas12a的生物传感器在个性化医疗中的研究和进一步发展提供见解。我们的研究结果表明,尽管基于CRISPR/Cas12a的生物传感器在各种应用和理论研究中具有巨大潜力,但仍存在一些挑战。这些挑战包括简化反应过程、提高精度、扩大疾病检测范围以及促进研究成果转化为临床实践。我们预计基于CRISPR/Cas12a的生物传感器的持续进步将解决这些挑战。